Entresto in children with chronic heart failure
Part of Heart & circulation clinical trials.
This study is for children with chronic heart failure who are starting Entresto for the first time. It helps doctors learn how well the medicine works and how safe it is for kids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be between 1 and 17 years old.
- You must be starting Entresto for the first time to treat chronic heart failure.
- A parent or guardian must sign a consent form before you start the medicine.
- You cannot have taken any medicine with the same ingredient as Entresto before.
- You must not have a history of allergic reaction to Entresto or its ingredients.
- You cannot be taking an ACE inhibitor (a type of blood pressure medicine) or have stopped one within the last 36 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called sacubitril-valsartan can improve heart structure and function in adults with congenital heart disease. You will take the drug and have heart imaging to see changes.
This study tests a new medicine called finerenone (a pill) to see if it helps children with heart failure who have a weak pumping heart. It compares finerenone to a placebo (a pill with no medicine) while both groups continue their usual heart treatments.
This trial studies whether sacubitril-valsartan works better than enalapril to improve heart healing after a specific type of heart attack. It aims to see if the heart’s shape and pumping recover more effectively.
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
This study tests a medicine called Jardiance (an SGLT2 inhibitor) to see if it helps improve heart function in adults with congenital heart disease who have recently experienced a drop in their heart pumping ability. Participants will take the medication alongside standard heart failure treatments.
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
Hear when a new Pediatric Chronic Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.